These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35927535)

  • 1. Exploring Patients' Understanding of Chemotherapy-Induced Peripheral Neuropathy.
    Knoerl R; Berry DL; Meyerhardt J; Reyes K; Salehi E; Gewandter JS
    J Cancer Educ; 2023 Jun; 38(3):906-912. PubMed ID: 35927535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring Chemotherapy-Induced Peripheral Neuropathy Management Practice Patterns Among Oncology Clinicians.
    Kanzawa-Lee G; Krauss JC; Knoerl R
    Semin Oncol Nurs; 2024 Oct; 40(5):151685. PubMed ID: 38937199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-Reported Severity, Characteristics, and Functional Limitations of Chemotherapy-Induced Peripheral Neuropathy.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    Pain Manag Nurs; 2022 Aug; 23(4):532-540. PubMed ID: 34972658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches.
    Knoerl R; Smith EML; Han A; Doe A; Scott K; Berry DL
    Patient Educ Couns; 2019 Sep; 102(9):1636-1643. PubMed ID: 31003878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experiences of cancer survivors with chemotherapy-induced peripheral neuropathy in the Netherlands: symptoms, daily limitations, involvement of healthcare professionals, and social support.
    van de Graaf DL; Engelen V; de Boer A; Vreugdenhil G; Smeets T; van der Lee ML; Trompetter HR; Mols F
    J Cancer Surviv; 2024 Oct; 18(5):1630-1639. PubMed ID: 37221391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
    Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
    BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
    Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
    Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy.
    Hertz DL; Tofthagen C; Rossi E; Bernasconi DP; Lim J; Carlson M; Sheffield KE; Nekhlyudov L; Grech L; Von Ah D; Mayo SJ; Ruddy KJ; Chan A; Alberti P; Lustberg MB; Tanay M
    Support Care Cancer; 2023 Dec; 32(1):48. PubMed ID: 38129602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol.
    Jang CE; Jung MS; Sohn EH; Kim M; Yoo HS; Bae K; Kim JR; Lee JS
    Trials; 2018 Sep; 19(1):526. PubMed ID: 30268158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP.
    Streckmann F; Balke M; Lehmann HC; Rustler V; Koliamitra C; Elter T; Hallek M; Leitzmann M; Steinmetz T; Heinen P; Baumann FT; Bloch W
    BMC Cancer; 2018 Jan; 18(1):62. PubMed ID: 29316888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
    Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
    JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring clinical markers of Axon degeneration processes in Chemotherapy-induced peripheral neuropathy among young adults receiving vincristine or paclitaxel.
    Knoerl R; Mazzola E; Pazyra-Murphy M; Ryback B; Frazier AL; Freeman RL; Hammer M; LaCasce A; Ligibel J; Luskin MR; Berry DL; Segal RA
    BMC Neurol; 2024 Sep; 24(1):366. PubMed ID: 39342135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data.
    Wang M; Molassiotis A
    Support Care Cancer; 2022 May; 30(5):4007-4017. PubMed ID: 35059866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
    Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB
    JAMA Netw Open; 2024 Aug; 7(8):e2424139. PubMed ID: 39120903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN).
    Hertz DL; Childs DS; Park SB; Faithfull S; Ke Y; Ali NT; McGlown SM; Chan A; Grech LB; Loprinzi CL; Ruddy KJ; Lustberg M
    Cancer Treat Rev; 2021 Sep; 99():102241. PubMed ID: 34174668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.
    Lee KM; Jung D; Hwang H; Son KL; Kim TY; Im SA; Lee KH; Hahm BJ
    J Psychosom Res; 2018 May; 108():14-19. PubMed ID: 29602320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.